Mirati Therapeutics Shares Tumble on Adagrasib Study Update >MRTX
marketwatch.com
news
2022-05-27 15:52:00

By Colin Kellaher Shares of Mirati Therapeutics Inc. slid more than 30% and hit a new 52-week low on Friday after the clinical-stage oncology company gave an update on a pivotal study of its product candidate adagrasib in non-small cell lung cancer that left investors disappointed. After the bell on Thursday, Mirati said initial results from the registration-enabling Phase 2 cohort showed an objective response rate of 43% and a median duration of response of 8.5 months in the second-line treatment of patients with non-small cell lung cancer harboring the KRAS(G12C) mutation.
